Vistagen Therapeutics, Inc.

NasdaqCM:VTGN Stock Report

Market Cap: US$69.6m

Vistagen Therapeutics Management

Management criteria checks 1/4

Vistagen Therapeutics' CEO is Shawn Singh, appointed in Aug 2009, has a tenure of 15.33 years. total yearly compensation is $947.92K, comprised of 65.7% salary and 34.3% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $78.41K. The average tenure of the management team and the board of directors is 1.8 years and 8.8 years respectively.

Key information

Shawn Singh

Chief executive officer

US$947.9k

Total compensation

CEO salary percentage65.7%
CEO tenure15.3yrs
CEO ownership0.1%
Management average tenure1.8yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely

Nov 15
We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

VistaGen initiates late-stage trial of PH94B in social anxiety disorder

May 26

VistaGen names new chief commercial officer

May 04

How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

Feb 16
How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

VistaGen Therapeutics regains Nasdaq listing compliance

Jan 06

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

CEO Compensation Analysis

How has Shawn Singh's remuneration changed compared to Vistagen Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$40m

Jun 30 2024n/an/a

-US$33m

Mar 31 2024US$948kUS$623k

-US$29m

Dec 31 2023n/an/a

-US$32m

Sep 30 2023n/an/a

-US$35m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023US$600kUS$600k

-US$59m

Dec 31 2022n/an/a

-US$64m

Sep 30 2022n/an/a

-US$65m

Jun 30 2022n/an/a

-US$60m

Mar 31 2022US$1mUS$563k

-US$49m

Dec 31 2021n/an/a

-US$62m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$47m

Mar 31 2021US$1mUS$511k

-US$42m

Dec 31 2020n/an/a

-US$16m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$19m

Mar 31 2020US$934kUS$498k

-US$22m

Dec 31 2019n/an/a

-US$24m

Sep 30 2019n/an/a

-US$26m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019US$951kUS$466k

-US$26m

Dec 31 2018n/an/a

-US$24m

Sep 30 2018n/an/a

-US$20m

Jun 30 2018n/an/a

-US$18m

Mar 31 2018US$1mUS$425k

-US$16m

Compensation vs Market: Shawn's total compensation ($USD947.92K) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Shawn's compensation has increased whilst the company is unprofitable.

CEO

Shawn Singh (61 yo)

15.3yrs

Tenure

US$947,917

Compensation

Mr. Shawn K. Singh, J.D. has been the Chief Executive Officer at VistaGen Therapeutics, Inc., since August 20, 2009. Mr. Singh serves as the Chief Business Officer and General Counsel at Cato Research Ltd....

Leadership Team

NamePositionTenureCompensationOwnership
Shawn Singh
CEO & Director15.3yrsUS$947.92k0.11%
$ 78.4k
Cynthia Anderson
VP & Chief Financial Officer1.3yrsUS$434.19k0.013%
$ 9.0k
Joshua Prince
Chief Operating Officer2.1yrsUS$568.44k0.0096%
$ 6.7k
Reid Adler
Chief Corporate Development Officer & General Counsel2.6yrsUS$675.00k0.059%
$ 41.3k
Mark McPartland
Senior Vice President of Investor Relations1.7yrsUS$479.99kno data
Trisha Fitzmaurice
Senior Vice President of Human Resourcesno datano datano data
Allen Cato
Senior Vice President of Development Operationsno datano datano data
Mark Ginski
Senior VP and Head of Chemistry3.8yrsno datano data
Mark Flather
Senior Vice President of Corporate Strategy & Capital Markets1.7yrsno datano data
Erik Berglund
Senior Vice President of Global Regulatory Affairs & Pharmacovigilance1.4yrsno datano data
Louis Monti
Senior Vice President of Translational Neuroscienceless than a yearno datano data
Jessica Haskell
VP, Associate General Counsel & Secretary1.9yrsno datano data

1.8yrs

Average Tenure

56yo

Average Age

Experienced Management: VTGN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Shawn Singh
CEO & Director13.9yrsUS$947.92k0.11%
$ 78.4k
Jon Saxe
Independent Director24.9yrsUS$129.37k0.0067%
$ 4.6k
Jerry Gin
Independent Director8.8yrsUS$128.12k0.048%
$ 33.3k
Gordon Keller
Chairman of Scientific Advisory Board2yrsno datano data
Thomas Laughren
Member of Clinical & Regulatory Advisory Board8.8yrsno datano data
Maurizio Fava
Member of Clinical & Regulatory Advisory Board9.2yrsno datano data
Michael Liebowitz
Member of CNS Clinical and Regulatory Advisory Board6.2yrsno datano data
Margaret FitzPatrick
Independent Chair of the Board3.4yrsUS$185.62k0%
$ 0
Mark Steven Wallace
Member of Clinical & Regulatory Advisory Board7.4yrsno datano data
Gerard Sanacora
Member of Clinical & Regulatory Advisory Board9.8yrsno datano data
Mary Rotunno
Independent Director3.4yrsUS$128.12k0%
$ 0
Sanjay Mathew
Member of Clinical & Regulatory Advisory Board8.8yrsno datano data

8.8yrs

Average Tenure

64yo

Average Age

Experienced Board: VTGN's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:58
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vistagen Therapeutics, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Gbolahan Amusa BenzChardan Capital Markets, LLC
Lin TsaiJefferies LLC